Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy
Li B, Tan T, Chu W, Zhang Y, Ye Y, Wang S, Qin Y, Tang J, Cao X
Drug delivery · 39 citas
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas, más trabajo en animales o laboratorio
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Anhui Province Natural Science Foundation
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-12-29 · Drug Deliv · vol. 29 · número 1 · págs. 75–88
- Editorial
- Taylor & Francis
- Citado
- 53 citas · más que el 93% de estudios similares · 2.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 54 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Cancer, Lipids, and Metabolism · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
- Palabras clave
- Paclitaxel, Docosahexaenoic acid, Nanocarriers, Cytotoxicity, Pharmacology, Drug delivery, Cancer cell, Toxicity, In vivo, Breast cancer, Apoptosis, Cancer, Cancer research, Chemistry, In vitro, Drug, Medicine, Fatty acid, Biology, Polyunsaturated fatty acid, Biochemistry, Internal medicine
- MeSH
- cell line, tumor, animals, mice, inbred balb c, humans, mice, mice, nude, paclitaxel, folic acid, antineoplastic agents, phytogenic, emulsions, drug carriers, xenograft model antitumor assays, apoptosis, cell survival, dose-response relationship, drug, female, nanoparticles, mcf-7 cells, drug liberation, raw 264.7 cells, tumor-associated macrophages
9 autores
- Bo Li🇨🇳Anhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
- Tingfei Tan🇨🇳Anhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
- Weiwei Chu🇨🇳Anhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
- Ying Zhang🇨🇳Anhui Medical University; First Affiliated Hospital of Anhui Medical University
- Yuanzi Ye🇨🇳Anhui Medical University; First Affiliated Hospital of Anhui Medical University
- Shanshan Wang🇨🇳Anhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
- Qin Yan🇨🇳Anhui Medical University
- Jihui Tang🇨🇳 · autor de correspondenciaAnhui Medical University
- Xi Cao🇨🇳 · autor de correspondenciaAnhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Breast cancer is one of the most common types of cancer in female patients with high morbidity and mortality. Multi-drug chemotherapy has significant advantages in the treatment of malignant tumors, especially in reducing drug toxicity, increasing drug sensitivity and reducing drug resistance. The objective of this research is to fabricate lipid nanoemulsions (LNs) for the co-delivery of PTX and docosahexaenoic acid (DHA) with folic acid (FA) decorating (PTX/DHA-FA-LNs), and investigate the anti-tumor activity of the PTX/DHA-FA-LNs against breast cancer both in vitro and in vivo. PTX/DHA-FA-LNs showed a steady release of PTX and DHA from the drug delivery system (DDS) without any burst effect. Furthermore, the PTX/DHA-FA-LNs exhibited a dose-dependent cytotoxicity and a higher rate of apoptosis as compared with the other groups in MCF-7 cells. The cellular uptake study revealed that this LNs were more readily uptaken by MCF-7 cells and M2 macrophages in vitro. Additionally, the targeted effect of PTX/DHA-FA-LNs was aided by FA receptor-mediated endocytosis, and its cytotoxicity was proportional to the cellular uptake efficiency. The anti-tumor efficiency results showed that PTX/DHA-FA-LNs significant inhibited tumor volume growth, prolonged survival time, and reduced toxicity when compared with the other groups. These results indicated that DHA increases the sensitivity of tumor cells and tumor-associated macrophages (ATM2) to PTX, and synergistic effects of folate modification in breast cancer treatment, thus PTX/DHA-FA-LNs may be a promising nanocarrier for breast cancer treatment.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.